President & CEO of the Alzheimer’s Association, Joanne Pike, DrPH sent the following message Friday: The Food and Drug Administration (FDA) has granted accelerated approval to lecanemab, brand name Leqembi, for patients confirmed to be in early stage Alzheimer’s disease. As we shared with you previously, rigorous clinical trials showContinue Reading